Combining CAR T-Cell Therapy and Nivolumab to Overcome Immune Resistance in THRLBCL: A Case Report

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Case report reveals CAR T-cell therapy's efficacy in THRLBCL challenged by PD-L1 overexpression, highlighting nivolumab's role.

Nivolumab combined with CAR T-cell therapy led to a complete metabolic response in a patient with THRLBCL.
After four doses of nivolumab, the 29-year-old patient remained in sustained remission four years post-treatment.
Comparative analysis showed significant PD-L1 expression post-CAR T-cell therapy, indicating immune resistance.
These findings suggest that checkpoint inhibition may improve outcomes in B-cell malignancies like THRLBCL.

Munárriz et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

View Full Paper

Ask AI

Bookmark

Authors

Case report reveals CAR T-cell therapy's efficacy in THRLBCL challenged by PD-L1 overexpression, highlighting nivolumab's role.

Nivolumab combined with CAR T-cell therapy led to a complete metabolic response in a patient with THRLBCL.
After four doses of nivolumab, the 29-year-old patient remained in sustained remission four years post-treatment.
Comparative analysis showed significant PD-L1 expression post-CAR T-cell therapy, indicating immune resistance.
These findings suggest that checkpoint inhibition may improve outcomes in B-cell malignancies like THRLBCL.

Munárriz et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark